Citadel Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.45B Sell
1,581,800
-507,000
-24% -$514M 0.24% 62
2025
Q4
$2.24B Sell
2,088,800
-140,600
-6% -$134M 0.34% 46
2025
Q3
$1.7B Buy
2,229,400
+508,900
+30% +$379M 0.26% 51
2025
Q2
$1.34B Buy
1,720,500
+71,000
+4% +$55.2M 0.23% 50
2025
Q1
$1.36B Sell
1,649,500
-207,200
-11% -$172M 0.26% 39
2024
Q4
$1.43B Buy
1,856,700
+415,000
+29% +$344M 0.25% 41
2024
Q3
$1.28B Buy
1,441,700
+249,500
+21% +$224M 0.25% 47
2024
Q2
$1.08B Sell
1,192,200
-240,000
-17% -$192M 0.22% 52
2024
Q1
$1.11B Sell
1,432,200
-162,500
-10% -$116M 0.21% 50
2023
Q4
$930M Buy
1,594,700
+235,300
+17% +$137M 0.19% 52
2023
Q3
$730M Buy
1,359,400
+44,900
+3% +$23.1M 0.16% 62
2023
Q2
$616M Buy
1,314,500
+557,600
+74% +$234M 0.13% 78
2023
Q1
$260M Sell
756,900
-614,800
-45% -$207M 0.06% 228
2022
Q4
$502M Sell
1,371,700
-1,110,100
-45% -$394M 0.12% 104
2022
Q3
$802M Buy
2,481,800
+1,629,100
+191% +$516M 0.18% 49
2022
Q2
$276M Sell
852,700
-84,800
-9% -$25.5M 0.07% 190
2022
Q1
$268M Sell
937,500
-37,200
-4% -$9.57M 0.06% 242
2021
Q4
$269M Sell
974,700
-122,900
-11% -$31.2M 0.06% 248
2021
Q3
$254M Buy
1,097,600
+3,100
+0.3% +$765K 0.05% 263
2021
Q2
$251M Buy
1,094,500
+234,700
+27% +$47.1M 0.06% 248
2021
Q1
$161M Sell
859,800
-121,900
-12% -$23.8M 0.04% 377
2020
Q4
$166M Buy
981,700
+488,000
+99% +$72.9M 0.04% 328
2020
Q3
$73.1M Sell
493,700
-177,900
-26% -$27.5M 0.02% 628
2020
Q2
$110M Sell
671,600
-46,200
-6% -$7.09M 0.04% 359
2020
Q1
$99.6M Sell
717,800
-156,400
-18% -$21.5M 0.04% 337
2019
Q4
$115M Buy
874,200
+372,300
+74% +$43.2M 0.05% 339
2019
Q3
$56.1M Buy
501,900
+151,500
+43% +$16.9M 0.03% 689
2019
Q2
$38.8M Sell
350,400
-325,900
-48% -$38.4M 0.02% 894
2019
Q1
$87.8M Buy
676,300
+47,700
+8% +$5.8M 0.04% 414
2018
Q4
$72.7M Buy
628,600
+23,000
+4% +$2.57M 0.04% 455
2018
Q3
$65M Buy
605,600
+389,800
+181% +$39M 0.03% 607
2018
Q2
$18.4M Sell
215,800
-29,600
-12% -$2.43M 0.01% 1378
2018
Q1
$19M Sell
245,400
-235,700
-49% -$19M 0.01% 1161
2017
Q4
$40.6M Buy
481,100
+266,100
+124% +$22.6M 0.02% 736
2017
Q3
$18.4M Sell
215,000
-50,000
-19% -$4.1M 0.01% 1121
2017
Q2
$21.8M Buy
265,000
+11,700
+5% +$955K 0.02% 952
2017
Q1
$21.3M Sell
253,300
-189,400
-43% -$15.2M 0.02% 912
2016
Q4
$32.6M Buy
442,700
+34,200
+8% +$2.55M 0.03% 583
2016
Q3
$32.8M Buy
408,500
+181,400
+80% +$14.5M 0.03% 596
2016
Q2
$17.9M Sell
227,100
-32,400
-12% -$2.44M 0.02% 856
2016
Q1
$18.7M Buy
259,500
+84,400
+48% +$6.39M 0.02% 785
2015
Q4
$14.8M Sell
175,100
-65,700
-27% -$5.45M 0.02% 1016
2015
Q3
$20.2M Buy
240,800
+65,300
+37% +$5.51M 0.02% 897
2015
Q2
$14.7M Sell
175,500
-13,100
-7% -$998K 0.01% 1221
2015
Q1
$13.7M Buy
188,600
+1,300
+0.7% +$92.6K 0.01% 1220
2014
Q4
$12.9M Buy
187,300
+61,900
+49% +$4.18M 0.01% 1222
2014
Q3
$8.13M Sell
125,400
-61,400
-33% -$3.89M 0.01% 1536
2014
Q2
$11.6M Sell
186,800
-4,900
-3% -$292K 0.01% 1150
2014
Q1
$11.3M Sell
191,700
-51,000
-21% -$2.85M 0.01% 1182
2013
Q4
$12.4M Sell
242,700
-49,900
-17% -$2.5M 0.02% 1083
2013
Q3
$14.7M Buy
292,600
+44,900
+18% +$2.35M 0.02% 878
2013
Q2
$12.2M Buy
+247,700
New +$13.5M 0.02% 942

Other funds holding LLY

Citadel Advisors's LLY Position: Q1 2026 in Review

Citadel Advisors reduced its Eli Lilly (LLY) stake by 65% in Q1 2026, selling an estimated $464M and leaving 241,714 shares worth $222M. The position accounts for 0.04% of the portfolio, ranked #410.

Citadel Advisors first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $880M in Q3 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Citadel Advisors held 241,714 shares of Eli Lilly worth $222M as of Q1 2026.
  • Citadel Advisors sold 458,045 Eli Lilly shares in Q1 2026, an estimated $464M.
  • Eli Lilly made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #410 holding.
  • Citadel Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Eli Lilly position peaked at $880M in Q3 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.